Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer

Not Applicable

Terminated

• Conditions: Bone Cancer
• Interventions: Radiation: fluorine F 18 sodium fluoride; Procedure: positron emission tomography/computed tomography

• Registration Number: NCT01541358
• Lead Sponsor: Stanford University

Brief Summary

This clinical trial studies fluorine F-18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) in diagnosing bone tumors in patients with cancer. Diagnostic procedures, such as fluorine F-18 sodium fluoride PET/CT, may help find and diagnose bone cancer

Detailed Description

The objective of the study is to use 18F sodium fluoride (fluorine F-18 sodium fluoride) PET/CT scanning to detect and characterize lesions in patients who have suspected skeletal malignancy. We hypothesize that scanning with 18F-NaF (fluorine F-18 sodium fluoride) is more sensitive for skeletal abnormalities and may better characterize lesions than conventional imaging.

Study Timeline

• Study First Submitted: 2012-02-23
• Study First Submitted QC: 2012-02-23
• Study First Posted: 2012-02-29
• Study Start: 2012-05
• Primary Completion: 2012-09
• Study Completion: 2012-09
• Results First Submitted: 2017-02-14
• Status Verified: 2017-05
• Results First Submitted QC: 2017-05-12
• Last Update Submitted: 2017-05-12
• Results First Posted: 2017-06-14
• Last Update Posted: 2017-06-14

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Patients referred for evaluation of suspected skeletal cancer
• Patients must understand and voluntarily sign an informed consent form after the contents have been fully explained to them

Read More

Exclusion Criteria

• Patients who cannot complete a PET/CT scan
• Pregnant women
• Healthy volunteers

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Diagnostic (fluorine F 18 sodium fluoride PET/CT)	fluorine F 18 sodium fluoride	Patients undergo fluorine F 18 sodium fluoride PET/CT scan.
Diagnostic (fluorine F 18 sodium fluoride PET/CT)	positron emission tomography/computed tomography	Patients undergo fluorine F 18 sodium fluoride PET/CT scan.

Primary Outcome Measures

Name	Time	Method
Total Number of Lesions Identified by F-18 NaF PET/CT in Patients With Suspected Skeletal Malignancy	an estimated average of 2 hours	F-18 NaF is a positron emission tomography (PET) bone imaging agent that targets changes in the bone. The fluoride ions are taken up in areas of the bone that have increased bone remodeling (bone repair) and increased blood flow, which is indicative of diseases such as cancer.

Secondary Outcome Measures

Name	Time	Method
Specificity of F-18 NaF PET/CT to Detect Bone Lesions in Patients With Suspected Skeletal Malignancy	an estimated average of 2 hours	Specificity is the ability of a test to correctly determine the absence of disease (true negative). This study determined how accurately F18 NaF PET/CT performed at detecting the absence of disease.; The calculation for specificity is TN / (TN + FP), where: TN = the participant was a true negative (the lesion was not detected on F18 NaF PET/CT and the patient does not have the disease) FP = the participant was a false positive (the lesion was falsely detected on the F18 NaF PET/CT and the patient does not have the disease) The result is expressed as a percentage.
Sensitivity of F-18 NaF PET/CT to Detect Bone Lesions in Patients With Suspected Skeletal Malignancy	an estimated average of 2 hours	Sensitivity is the ability of a test to correctly identify those with the disease (true positive rate). This study determined how many lesions were detected by F18 NaF PET/CT compared to the known results. The calculation for sensitivity is TP / (TP+FN), where: TP = true positive (the lesion was accurately detected on both F18 NaF and comparison study) FN = false negative (the lesion was not detected on the PET/CT but was detected on the comparison study); The result is expressed as the percentage of confirmed lesions across all participants that were also detected by F18 NaF PET/CT.

Trial Locations

Locations (1)

Stanford University; 🇺🇸 Stanford, California, United States